Ирина Александровна Акулова

Ирина Александровна Акулова

Auto-generated profile, based on publicly available information

Ирина Александровна Акулова

N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
DUD.G. Ulrikh
D.G. Ulrikh
PKP.V. Krivorotko
P.V. Krivorotko
ZBZh.V. Bryantseva
Zh.V. Bryantseva
RPR.S. Pesotskiy
R.S. Pesotskiy
YBY.I. Bondarchuk
Y.I. Bondarchuk
VSV.F. Semiglazov
V.F. Semiglazov
Background. Breast reconstruction after mastectomy must consider potential complications from surgical techniques as well as additional complications that may arise from oncologic treatment steps such as radiation or systemic therapy. But the consensus is lacking regarding the optimal reconstruction plan for patients requiring adjuvant radiation therapy. Objective. To determine the impact of risk factors on the development complications of breast reconstruction for postmastectomy radiotherapy. Material and methods. This study included patients diagnosed with breast cancer who received combination treatment from 2016 to 2021 at the N.N. Petrov National Medical Research Center of Oncology. The patients were divided into 3 groups: immediate reconstruction (158 people), immediate-delayed (210 people) and delayed (98 people). Results. Every fourth patient (24.0%, 112/466) may encounter a complication after mastectomy with reconstruction and adjuvant radiation therapy. According to the analyzed data, there was no correlation between potential risk factors depending on the general status of patients (age, obesity, diabetes mellitus, hypertension, history of smoking) and the occurrence of complications after combination treatment. Conclusion. The analysis of complications and reconstructive failures showed that immediate breast reconstruction at the N.N. Petrov National Medical Research Center of Oncology is the safest method of reconstruction in the combined treatment of breast cancer with the lowest incidence of severe complications, which plays a key role in the development of reconstructive failures. However, these surgeries are associated with a significant number of capsular contractures, which requires finding ways to minimize these risks to optimize treatment in each individual case in short and long term.

1 December 2022 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
NPN. S. Popova
N. S. Popova
SNS. N. Novikov
S. N. Novikov
PKP. I. Krzhivitskiy
P. I. Krzhivitskiy
LZL. A. Zhukova
L. A. Zhukova
ПКП. В. Криворотько
П. В. Криворотько
SKS. V. Kanaev
S. V. Kanaev
Background. The accurate and early diagnosis of breast cancer can improve efficacy of the treatment. The standard diagnostic methods such as mammography, ultrasound, and magnetic resonance tomography have a pivotal role in the detection of breast tumors, however, in some cases, they have low diagnostic accuracy. Mammoscintigraphy (MSG) / molecular breast imaging (MBI) with tumor-specific radiopharmacy 99mTc-Technetril in patients with breast cancer can considerably increase the accuracy of diagnosis. However, the diagnostic performance of MSG / MBI in the detection of different biological subtypes of breast cancer is still under investigation.Aim. To evaluate the accuracy of MSG / MBI with 99mTc-Technetril in diagnosis of different biological subtypes of breast cancer.Materials and methods. The analysis included the results of MSG / MBI of 1080 patients (2154 mammary glands), who were examined for suspected breast cancer. MSG / MBI were performed 5–15 min after intravenous injection into the vein of one of the feet of 370–740 MBq of tumor-specific radiopharmacy 99mTc-Technetril. Examinations performed from 2007–2020 was carried out on the emission computed tomography Forte (Philips); since 2020 the molecular visualization has been providing on the special gamma-camera Discovery NM750b (General Electric). The obtained data were evaluated by 2 experienced radiologists. Verification of changes in breasts was provided by morphological examination (1060 cases) or dynamic observation.Results. The sensitivity, specificity and overall accuracy of MSG / MBI were 90 %, 98 %, 95 % correspondingly. When diagnosing tumors with a diameter of up to 10 mm, the sensitivity of MSG / MBI was decreased to 83 %. In patients with various biological subtypes, the sensitivity of MSG / MBI was as follows: luminal A – 88 %; luminal B– – 91 %; luminal B+ – 92 %; triple negative – 93 %; HER2-positive – 96 %. The intensity of tumor uptake depended on the biological subtype of breast cancer. The average values of the 99mTc-Technetril uptake coefficient were as follows: luminal A – 1.59; luminal B– – 1.71; luminal B+ – 1.95; triple negative – 1.93; HER2-positive – 2.22.Conclusion. Retrospective analysis indicate high diagnostic performance of MSG / MBI: sensitivity – 90 %, specificity – 98 %, accuracy – 95 %. There are significant differences in the intensity of 99mTc-Technetril accumulation in tumors in patients with different biological subtypes of breast cancer (p = 0.01–0.004). MSG / MBI characterized by significant differences in the sensitivity in the diagnosis of luminal A and HER2+ breast cancer subtypes: 88 % and 96 %, respectively (p = 0.02).

25 July 2024 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
ZBZh. V. Bryantseva
Zh. V. Bryantseva
SNS. N. Novikov
S. N. Novikov
DUD. G. Ulrikh
D. G. Ulrikh
ПКП. В. Криворотько
П. В. Криворотько
IAI. A. Akulova
I. A. Akulova
KZK. Yu. Zernov
K. Yu. Zernov
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.

6 May 2024 in Voprosy onkologii
Verified
Journal Article
Open access
ПКПетр Владимирович Криворотько
Петр Владимирович Криворотько
NANikolay Amirov
Nikolay Amirov
АААнна Сергеевна Артемьева
Анна Сергеевна Артемьева
ЕБЕкатерина Александровна Бусько
Екатерина Александровна Бусько
ТТТенгиз Тенгизович Табагуа
Тенгиз Тенгизович Табагуа
АБАлексей Михайлович Беляев
Алексей Михайлович Беляев
Introduction. Current opinion is that surgery is diagnostic rather than curative and does not affect long-term outcomes in breast cancer (BC) patients with complete pathomorphological response (pCR) after neoadjuvant systemic therapy (NST). As a minimally invasive method for diagnosing pCR in BC, vacuum-assisted biopsy (VAB) of the tumour bed has shown promising results. This paper presents a retrospective analysis of the outcomes of patients with triple-negative and HER2-positive BC who achieved pCR after NST according to different types of invasive breast surgery, including patients who underwent VAB alone without subsequent breast surgery. Materials and methods. From 1 January 2021 to 1 July 2023, we analysed 3247 patients who underwent surgery at the Department of Breast Tumours at the N.N. Petrov NMRC of Oncology. Patients were included in the study if they had unifocal invasive HER2+ and TNBC (cT1-2N0-1M0) with histologically confirmed pathological complete response (ypT0N0) to NST. Exclusion criteria were an intraductal component detected by trephine bone marrow core biopsy and germline mutations in BRCA1/2. According to the planned analysis, all patients were divided into three groups: the breast-conserving surgery (BCS) group, the mastectomy (ME) group and the VAB group. Primary endpoint was 2-year ipsilateral breast tumour recurrence-free survival [IBTR-FS]. Secondary endpoints included 2-year disease-free survival (DFS) and complication rates. Results. Of the 3 247 patients analyzed, 81 patients who met the inclusion criteria were included in the final analysis. There were 39 patients in the BCS group, 19 patients in the ME group, and 23 patients in the VAB group. The median follow-up was 24 months. The median survival was not reached for any of the endpoints. 2-year IBTR-FS was 100 % in the BCS group vs. 100 % in the ME group vs. 91.3 % in the VAB group [p = 0.159]. 2-year DFS was 97.4 % in the BCS group vs 94.7 % in the ME group vs 87.0 % in the VAB group [p = 0.396]. There was no difference in the hazard ratio (HR) for recurrence between the different types of surgery. When measuring HR adjusted for lymph node status (cN) and disease stage, there was a statistically significant higher risk in the VAB group [HR adjusted for cN: 12.236, (95 % CI, 1.163-128.773), p = 0.037; HR adjusted for stage: 17.071, (95 % CI, 1.255-232.173), p = 0.033]. Conclusion. To determine the safety of VAB use, further observational studies and large randomised prospective trials are needed. There was no significant difference in the incidence of complications between the different types of invasive procedures in this cohort of patients. Введение. В настоящее время существует точка зрения, согласно которой у пациентов с диагнозом рак молочной железы (РМЖ) выполнение хирургического вмешательства при достижении полного патоморфологического ответа (pCR) после неоадъювантной системной терапии (НСТ) носит диагностический, а не лечебный характер, и не влияет на отдаленные результаты лечения. Вакуум-ассистированная биопсия (ВАБ) ложа опухоли при РМЖ показала многообещающие результаты в качестве малоинвазивного метода диагностики pCR. В этой работе представлен ретроспективный анализ результатов лечения пациентов с трижды-негативным и HER2-позитивным РМЖ, достигших pCR после НСТ, в зависимости от различных видов инвазивного вмешательства на молочной железе, включая пациентов, которым была проведена только ВАБ без последующего хирургического вмешательства на молочной железе. Материалы и методы. За период с 01 января 2021 г. по 01 июля 2023 г. проанализировано 3 247 пациентов, которым выполнено хирургическое вмешательство в отделении опухолей молочной железы на базе ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России. В исследование включались пациенты с унифокальным инвазивным HER2+ и ТНРМЖ (cT1–2N0–1M0), у которых гистологически подтвержден полный патоморфологический ответ (ypT0N0) на НСТ. В анализ не включались пациентки в случае выявления внутрипротокового компонента, по данным трепан-биопсии, а также в случае носительства наследственных мутаций в генах BRCA1/2. В соответствии с запланированным анализом все пациенты были разделены на три группы: группа органосохраняющих операций (ОСО), группа мастэктомий (МЭ), группа ВАБ. В качестве первичной конечной точки оценивалась двухлетняя выживаемость без рецидива в ипсилатеральной молочной железе [IBTR-FS]. Вторичные конечные точки включали двухлетнюю безрецидивную выживаемость (DFS) и частоту...

2 September 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
НПНадежда Попова
Надежда Попова
СНСергей Новиков
Сергей Новиков
ПКПавел Крживицкий
Павел Крживицкий
ЛЖЛюдмила Жукова
Людмила Жукова
ПКПетр Криворотько
Петр Криворотько
СКСергей Канаев
Сергей Канаев
Цель. Определение информативности сцинтимаммографии/молекулярной визуализации (МСГ/МВ) при выявлении минимальных форм (МФ) рака молочной железы (РМЖ), а также установление частоты визуализации мультицентричного (МЦ) опухолевого процесса у больных с различными биологическими подтипами РМЖ. Материалы и методы. В анализ вошли результаты МСГ/МВ 1080 женщин (2 154 молочных желез), обследованных в связи с подозрением на наличие РМЖ. Радионуклидные исследования — МСГ/МВ выполнялись через 15-20 минут после введения в вену одной из стоп 370-740 МБк 99mTc-«MIBI». Верификация изменений в 1 060 случаях осуществлялась с помощью морфологического исследования, в остальных — при динамическом наблюдении. К МФ РМЖ относили все гистологически подтвержденные опухолевые очаги размерами до 10 мм. Сцинтиграфическими признаками МЦ опухолевого процесса считали наличие двух или более очагов, локализованных в разных квадрантах и/или одном квадранте, но на расстоянии не менее 30 мм друг от друга. Результаты. Чувствительность МСГ/МВ в диагностике МФ РМЖ в целом составила 82 %. У больных с различными биологическими подтипами РМЖ чувствительность МСГ/МВ составила 76 % при люминальном А; 80 % и 91 % — при люминальных В «-» и «+» подтипах, 90 % и 100 % — при трижды негативном и HER2 позитивном подтипах соответственно. Показатели чувствительности метода в диагностике минимальных форм трижды негативного и HER2 позитивного РМЖ оказались достоверно выше, чем в диагностике люминальных А и В-подтипов (p = 0,02). Частота визуализации МЦ РМЖ в зависимости от биологических подтипов различалась: при HER2 позитивном - 19 случаев (20,2 %), что достоверно выше (р = 0,006), чем при других молекулярно-биологических подтипах: люминальный A — 25 (10,5 %), люминальный B — 41 (11,4 %), люминальный B+ — 19 (12,6 %), трижды негативный — 18 случаев (10,3 %). Выводы. Определяется достоверное увеличение чувствительности МСГ/МВ при диагностике МФ РМЖ наиболее агрессивных биологических подтипов: 90% - при трижды негативном и 100% - при HER2 позитивном РМЖ. Установлена наиболее высокая частота визуализации МЦ РМЖ у больных с HER2+ подтипом РМЖ (20,2 %).

18 September 2024 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
ZBZh. V. Bryantseva
Zh. V. Bryantseva
IAI. A. Akulova
I. A. Akulova
TYT. S. Yaganova
T. S. Yaganova
DUD. G. Ulrikh
D. G. Ulrikh
TTT. T. Tabagua
T. T. Tabagua
SNS. N. Novikov
S. N. Novikov
Purpose: To compare dosimetric plans obtained in patients with breast cancer (BC) that underwent accelerated partial breast irradiation (APBI) by conformal external beam radiotherapy (EBRT) or interstitial high dose rate brachytherapy (HDRB).Material and methods: From 2017 to 2022 APBI was performed in 210 patients with stage I–II BC (рТ1N0M0–pT2N0M0). APBI was delivered to the tumor bed: in 99 cases — by EBRT, in another 111 patients — by HDRB. Leſt breast was irradiated in 101 women: in 51 women using HDRB, in 50 patients — by EBRT. Following dosimetric parameters were used for comparison of the dosimetric plans: Dmax – maximum dose in the organ at risk; Dmed – mean dose in the organ at risk (heart, leſt main coronary artery and its descending branch, ipsilateral lung, breast, skin and subcutaneous tissues).Results: When the tumor bed was irradiated by HDRB, in comparison with EBRT, Dmax for the skin and subcutaneous tissue decreases from 98.4 % to 68.7 %, р < 0.002. The use of HDRB made it possible to reduce the radiation load on the ipsilateral lung: Dmax decreased from 71.9 % to 42.7 % , р < 0.002; Dmed was 5.5 % for HDRB and 2.9 % for EBRT, р > 0.05. On the contrary EBRT associated with higher dose to the breast Dmed breast — 46 % in comparison with HDRB Dmed breast — 16.5 % , р < 0.002. Dose to the heart was higher with HDBT Dmax heart — 20.2 %, Dmed heart was 4.9 % than with EBRT Dmax heart — 14.4 %, Dmed heart — 0.8 %. Dose to the left coronary artery with HDRB Dmax — 6.5 % , Dmed — 3.9 % was higher than with EBRT Dmax — 3.3 % , Dmed — 1.3 % . Dose to the descending branch of the left coronary artery was higher with HDRB Dmax — 12.6 % , Dmed — 9.3 % than with EBRT Dmax — 8.9 % and Dmed — 3.4 % . But this differences were non-significant (р > 0.05).Conclusions. APBI by HDRB associated by significant reduction of the radiation dose to the ipsilateral breast lung, breast, skin and subcutaneous tissues.